tbuckley/cabot-search huggingface dataset:
Abstract 4246: Dobutamine-induced Reserve of the Two-dimensional Longitudinal Strain Rate Predicts Clinical and Neurohumoral Improvement After Levosimendan Treatment in Acutely Decompensated Chronic Heart Failure
Authors: Vasiliki Bistola, Ioannis Paraskevaidis, Ignatios Ikonomidis, Ioannis Parissis, Gerasimos Filippatos, Dimitrios T Kremastinos
Journal: Circulation (2008)

Objective: Levosimendan improves symptoms and the hemodynamic profile in patients with acutely decompensated chronic heart failure (ADCHF). We aimed to investigate: the association of low dose dobutamine (DSE)-induced changes of two-dimensional strain parameters with the corresponding changes of left ventricular ejection fraction (LVEF) and left ventricular outflow tract velocity time integral (LVOT VTI) in patients with ADCHF, and whether left ventricular contractile reserve assessed by both conventional and speckle tracking echocardiography is associated with clinical and neurohumoral improvement after levosimendan treatment. Methods: Thirty one consecutive patients with ADCHF (mean age 65 ± 10 years, NYHA class 3.6 ± 0.3, LVEF 22 ± 6%) were studied by DSE (peak dose 20 μg/kg/min) prior to 24-hour infusion of levosimendan (0.01 μg/kg/min, without bolus). The LVEF, LVOT VTI, mean longitudinal, circumferential and radial strain and strain rate using speckle tracking imaging were measured. Results: Twenty-three patients (74%) had evidence of contractile reserve (increase of LVEF &gt; 10% and LVOT VTI &gt; 20% after peak dobutamine dose, CR+), and 8 (26%) showed no reserve (CR−). CR+ versus CR- patients demonstrated greater improvement of NYHA class (mean NYHA change: −1.0±0.5 vs −0.5±0.3 NYHA class, p=0.01), and reduction of b-type natriuretic peptide levels (− 34±30 vs + 4±31%, p &lt;0.01) 48 hours after completion of treatment. By multivariate analysis, mean longitudinal systolic strain rate reserve (resting - peak longitudinal strain rate ΔLSR (%)) was the best predictor of improvement of NYHA class (p= 0.039) and BNP (p= 0.042) after levosimendan administration among the reserve of: LV FS, EF, LVOT VTI, longitudinal strain, circumferential and radial strain and strain rate. Conclusion: Dobutamine-induced reserve of 2-dimentional speckle tracking longitudinal systolic strain rate is associated with clinical and neurohumoral improvement after treatment with levosimendan in patients with ADCHF.
How many new treatments are “breakthroughs”? Evaluation of innovations in cancer
Authors: A. Kumar, H. P. Soares, F. Serdarevic, I. Hozo, J. C. Buckner, R. J. Wells, J. Fiorica, S. Swan, D. Sargent, B. Djulbegovic
Journal: Journal of Clinical Oncology (2005)

6066 Background: Research efforts tested in randomized controlled trials (RCT) have played a vital role in the development of new treatments for cancer. The research conducted by the National Cancer Institute (NCI) cooperative groups (CG) is universally considered of vital importance to this progress. However, how often new interventions tested in the NCI-CG-RCTs are highly successful or “breakthrough” is not known. Methods: All completed phase 3 RCTs (563 trials, ∼149,000 patients) conducted by 6 NCI-CGs was reviewed. Published and unpublished data were used. Breakthroughs were defined in two ways: semi-quantitatively (score 1–6): the intervention was so successful according to the original researchers that it should be adopted immediately as a new therapeutic standard (=6), and quantitatively: the intervention effect resulted in a log hazard ratio of ≤ -0.5 in terms of survival or event-free survival. Results: According to the original investigators, 14% (n=81) of experimental testing resulted in breakthrough. 7% of interventions dramatically improved survival in terms of log hazard ratio of ≤ -0.5, while 13% led to a similar improvement in event-free survival. By disease, quantitatively (23%) and semi-quantitatively (12%) the highest number of breakthroughs were for leukemias. Induction and curative therapies jointly resulted in 62% and 73% of breakthroughs by quantitative and semi-quantitative assessment, respectively. 15% of childhood vs. 5% of adult cancer trials resulted in dramatic survival improvements. However, assessing semi-quantitatively, there were 18% and 14% breakthroughs in childhood and adult cancers, respectively. Conclusions: 14% of the experimental treatments that progressed to testing in RCTs resulted in discovery of breakthrough interventions. This is the first comprehensive assessment of success of innovative therapies in cancer and in clinical medicine. No systematic research was found in the literature permitting to contrast our findings with the estimate of the proportion of breakthrough interventions from non-RCT, phase I & II trials. Researchers, physicians, policy makers and the public should understand what it takes to produce a successful, breakthrough intervention in cancer. No significant financial relationships to disclose.
The X-Ray Atlas of the Systemic Arteries of the Body.
Authors: H. C. Orrin
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2568: Metabolic Control of Cardiac Na+ Current Through Pyridine Nucleotides
Authors: Man Liu, Iman Gurung, Xiaodong Zhu, Georgia Gaconnet, Shamarendra Sanyal, Christopher L Huang, Andrew Grace, Barry London, Samuel Dudley
Journal: Circulation (2009)

Background: Mutations in glycerol-3-phosphate dehydrogenase 1-like (GPD1-L) protein reduce cardiac Na+ current (INa) and cause Brugada Syndrome. GPD1-L has >80% amino acid homology with glycerol-3-...
Cancer: A General Guide to Research and Its Treatment.
Authors: Nikolai Nikolaevich Petrov, A. P. Fletcher
Journal: Annals of Internal Medicine (1963)

structure, and that 'diverticula' found in the intercapillary lumina are pressoreceptors transmitting information to the juxtaglomerular apparatus.This work is likely to have a limited appeal to British pathologists unless they are working in the renal field.
Abstract 549: ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) Trial: Early vs. Late Experience
Authors: James M Maher, Vivek N Dhruva, Pallavi Solanki, Ramzan Zakir, Edo Kaluski, Marc Klapholz
Journal: Circulation (2008)

Background: We previously reported our early (initial 6 month) experience using a fully automated wireless network to shorten door to intervention (D2I) times. Later experience allowed for further refinement of this network. Early D2I times are expected to result in smaller infarcts and decreased lengths of stay. Methods: A fully automated wireless network that facilitates simultaneous 12-lead ECG transmission from emergency medical services (EMS) personnel in the field to the Emergency Department (ED) and offsite cardiologists via smart phones. This allows direct communication between offsite cardiologist and EMS and facilitates patient triage directly to the cath lab. Demographic, laboratory and time interval data were prospectively collected over a 23-month period and compared to calendar year 2005 data. Early experience (first 6 months) was compared to later experience. Results: From June 2006 through April 2008, 242 ECGs with suspected ST segment elevation myocardial infarction (STEMI) were transmitted via the STAT-MI network. Compared with 2005 data, door to cardiology notification time was reduced from 61.4 minutes (min) to −15.8 min (p &lt; 0.001), door to arterial access time decreased from 108.1 to 42.1 min (p &lt; 0.0001), door to intervention (D2I) time decreased from 145.7 to 68.8 min (p = 0.00001), hospital length of stay decreased from 5.4 ± 4.5 days to 4.1 ± 5.0 days (p &lt; 0.29), and troponin elevation decreased from 106.4 ng/ml to 73.9 ng/ml (p &lt; 0.19). The magnitude of timesavings was similar regardless of time of presentation, though D2I times were longer during “off” hours (after 5pm and weekends) as compared to “on” hours (85.7 min vs. 51.8 min P=0.001). Protocol refinements introduced over the first 6 months further shortened D2I times; 87 min vs 65 min in the first 6 months and in the subsequent 17 months respectively (p = 0.09). Conclusions: A fully automated wireless network that transmits ECGs simultaneously to the ED and offsite cardiologists for the early evaluation and triage of patients with STEMI markedly and consistently shortened D2I times. A strong positive trend in outcome measures was also observed with reduced length of stay and smaller infarct size. There was a 6 month learning curve to fully realize the benefits of this new automated system.
Labelled Atoms: The Use of Radioactive and Stable Isotopes in Biology and Medicine
Authors: Raymond Glascock
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Glioma Groups Based on 1p/19q,<i>IDH</i>, and<i>TERT</i>Promoter Mutations in Tumors
Authors: Jeanette E. Eckel-Passow, Daniel H. Lachance, Annette M. Molinaro, Kyle M. Walsh, Paul A. Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L. Kosel, Ivan V. Smirnov, Gobinda Sarkar, Alissa A. Caron, Thomas M. Kollmeyer, Corinne E. Praska, Anisha R. Chada, Chandralekha Halder, Helen M. Hansen, Lucie S. McCoy, Paige M. Bracci, Roxanne Marshall, Shichun Zheng, Gerald F. Reis, Alexander R. Pico, Brian P. O’Neill, Jan C. Buckner, Caterina Giannini, Jason T. Huse, Arie Perry, Tarik Tihan, Mitchell S. Berger, Susan M. Chang, Michael D. Prados, Joseph Wiemels, John K. Wiencke, Margaret R. Wrensch, Robert B. Jenkins
Journal: New England Journal of Medicine (2015)

The prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants.We scored tumors as negative or positive for each of these markers in 1087 gliomas and compared acquired alterations and patient characteristics among the five primary molecular groups. Using 11,590 controls, we assessed associations between these groups and known glioma germline variants.Among 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. The mean age at diagnosis was lowest (37 years) among patients who had gliomas with only IDH mutations and was highest (59 years) among patients who had gliomas with only TERT mutations. The molecular groups were independently associated with overall survival among patients with grade II or III gliomas but not among patients with grade IV gliomas. The molecular groups were associated with specific germline variants.Gliomas were classified into five principal groups on the basis of three tumor markers. The groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis. (Funded by the National Institutes of Health and others.).
Glycogène, adrénaline et insuline.
Authors: M. Jacot
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1677: Adiponectin as a Biomarker at Different Stages of Ischaemic Heart Disease: From Obesity to Ischaemic Heart Failure
Authors: Alexis S Antonopoulos, Charalambos Antoniades, Dimitris Tousoulis, Antigoni Miliou, Constantinos Bakogiannis, Kyriakoula Marinou, Michalis Demosthenous, Costas Psarros, Keith M Channon, Christodoulos Stefanadis
Journal: Circulation (2009)

Background: Adiponectin is downregulated in obesity, but the existing data regarding its role at different stages of ischaemic heart disease have been conflicting. We evaluated the impact of obesit...
The Oxford Companion to Medicine.
Authors: John Nicholas Walton, Paul B. Beeson, Scott, Ronald Bodley, Sir, S. G. Owen, Philip Rhodes
Journal: Annals of Internal Medicine (1988)

Edited by three eminent physicians who are also noted medical writers, this encyclopedic collection contains over 10,000 entries ranging from major essays to short definitions, all written in language that is readily accessible to health care professionals and lay readers. Written by over 150 medical experts from the United States and the United Kingdom, the entries consider the historical developments and state-of-the-art of the major medical disciplines; discuss the academic, educational, and administrative structure of the profession and its relations to government and the law; and include numerous contributions to medicine, and definitions of common medical terms. Designed not only as a serious reference but also as a source of interesting and curious facts, the Companion contains detailed reviews of topics such as biochemistry, genetics, medical ethics, and surgery, interspersed with more leisurely entries on Music and Medicine, Cults and Quackery, and Bernadette of Lourdes. Encyclopedic in scope, this two-volume work will provide anyone interested in medicine with a fascinating and informative survey of the field. Selected entries: Addiction . Anatomy . Art &  . Clinical Chemistry . Computers in Clinical  . Death, Dying, and the Hospice Movement . Doctors as Patients . Ethical Issues . Foundations, Charities and Grant-Making Bodies . Genetics . Geriatrics . Government &  . Hematology . Insurance . Intensive Care . Law &  . Medical Books and Libraries . Medical Education . Medical Journals . Microbiology . Music &  . Neurology and the Neurological Sciences . Nuclear  . Nursing . Pain . Pharmacology, Clinical Pharmacology & Therapeutics . Psychology in Relation to  . Sports and  . Tropical  . Ultasonics . Women in Medicine
Chirurgie der Sportunfälle.
Authors: Felix. Mandl
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening for Lung Cancer with Low-Dose CT — Translating Science into Medicare Coverage Policy
Authors: Joseph Chin, Tamara Syrek Jensen, Lori Ashby, Jamie Hermansen, Joseph D. Hutter, Patrick H. Conway
Journal: New England Journal of Medicine (2015)

Thanks to recent evidence that screening with low-dose computed tomography reduces lung-cancer mortality, at-risk U.S. patients 55 to 77 years of age are now eligible for a screening benefit under Medicare, while further data are collected and assessed.
Mineral metabolism; an advanced treatise.
Authors: C. L. Comar, Felix Bronner
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14030: Hypertophic Cardiomyopathy in the Young: Patterns and Distribution of Hypertrophy
Authors: Jonathan D Windram, Lars Grosse-Wortmann, Masoud Shariat, Andreea Dragulescu, Shi-Joon Yoo, Lee Benson
Journal: Circulation (2011)

Background Patterns and distribution of hypertrophy in hypertrophic cardiomyopathy (HCM) has been well categorized in the adult population but not systematically described in children and teenagers...
Cisplatin (C), temozolomide (T) every 21 days and concomitant thalidomide (TH) in patients (PTS) with malignant gliomas. Final results of a phase I study
Authors: F. Zustovich, G. Cartei, R. Ceravolo, F. Salmaso, S. Zovato, S. Binato, D. Pastorelli
Journal: Journal of Clinical Oncology (2005)

1554 Background - Pre-clinical evidence shows synergism between C and T because of higher inhibition of O6-methylguanine-DNA methyl-transferase, enzyme involved in the miss-match repair system. T is active against malignant gliomas and Th is emerging as an inhibitor of angiogenesis. PTS - 14 : 11 Glioblastomas (GB), 2 Anaplastic Astrocytomas grade 3 (AA) and 1 Anaplastic meningo-sarcoma (AMS); 9 male; median age 56.2(range 34.3–74.7). ECOG PS/#PTS: 0/3; 1/5; 2/5; 3/1. Eight PTS with GB had previous surgery, 10 had radiotherapy and PTS with AA and AMS had both. Methods - See table. All Pts received i.v. C 75 mg/m2 d1 and oral T at escalating dose starting from 100 mg/m2 orally dd1–5, every 21 days. By level 3 Pts received orally TH starting from 50mg total day dose continuously. Haematological toxicity was assessed the day before next cycle. Results - See table. A total of 64 cycles were delivered; 12 cycles were delayed by a week because of WBC/PLT g3 reduction. All 14 PTS were valuable for toxicity. WHO G1–2 tox was(type/#PTS): anemia/9; nausea/6; vomiting/4; allergic/4 (Cutaneus/3 and Dyspnoea/1, only PTS receiving TH); fatigue/3; uditive/2; epigastralgia/2; thrombocytopenia/2; granulocytopenia/2; artralgia/1; myalgia/1; somnolence/1;. WHO G 3–4 tox was: granulocytopenia/6 (febrile G4/1); vascular venous/3 (DVT/2 and PE/1, only PTS receiving TH); thrombocytopenia/1. All 11 PTS with GB are valuable for RR: 1 PR; 6 SD; 4 PD. Eight out of 11 PTS were valuable for TTP and OS: median TTP=3.5 mos (range 0.9–6.3); median OS=12.6 mos (range 2.8–24.9). A Pt with GB who gained PR has a PFS of 5.4+ mos. Two of 3 PTS with AA III has been treated in adjuvant setting and had respectively a TTP of 5.2 and a PFS of 23.9+ mos. Conclusion: level 2 C and T every 21 days is feseable and safe as well as level 4 concomitant TH. A level 4 fase II study is ongoing. No significant financial relationships to disclose.